Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TERT | O14746 | 4/20 | 0.42 |
| ▸ | PIEZO1 | Q92508 | 10/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15599488 | 0.77 | KDM4E (0.50) | KDM4EHSD17B10TERTPIEZO1MEN1 | |
| SCHEMBL16543489 | 0.76 | KDM4E (0.50) | KDM4EHSD17B10MEN1ALDH1A1KMT2A | |
| SCHEMBL579479 | 0.73 | KDM4E (0.47) | KDM4EHSD17B10TERTPIEZO1MEN1 | |
| SCHEMBL26671383 | 0.72 | KDM4E (0.47) | KDM4EHSD17B10TERTPIEZO1MEN1 | |
| SCHEMBL16997515 | 0.71 | NPC1 (0.59) | KDM4EHSD17B10ALDH1A1KMT2A | |
| SCHEMBL16997495 | 0.71 | CNR2 (0.36) | KDM4ECNR2 | |
| SCHEMBL14369743 | 0.70 | KDM4E (0.53) | KDM4EHSD17B10MEN1ALDH1A1KMT2A | |
| SCHEMBL26777790 | 0.70 | KDM4E (0.48) | KDM4EHSD17B10TERTPIEZO1MEN1 | |
| SCHEMBL16997526 | 0.69 | TP53 (0.63) | KDM4EHSD17B10MEN1ALDH1A1MAPT | |
| SCHEMBL19984983 | 0.69 | KDM4E (0.47) | KDM4EHSD17B10TERTPIEZO1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505749-B2 | Quinazolinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150225396-A1 | Quinazolinone Compounds and Derivatives Thereof | AMGEN INC. | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225396-A1 | Quinazolinone Compounds and Derivatives Thereof | TNKS, TPI1, TNKS1BP1 | KDM4E 603/4885HSD17B10 2865/4885TERT 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.